No Data
No Data
BioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5,
United States Hereditary Angioedema Therapeutics Market Report 2024: Trends, Dynamics, Competition, Forecast and & Opportunities, 2019-2029F - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Hereditary Angioedema Therapeutics Market, By Region, Competition, Forecast and & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.
BioCryst Pharmaceuticals' (NASDAQ:BCRX) Growing Losses Don't Faze Investors as the Stock Spikes 18% This Past Week
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.2x BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is definitely a stock worth checking out, seeing as almost half of all the Biotechs
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
BofA Securities analyst Tazeen Ahmad maintains $BioCryst Pharmaceuticals(BCRX.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate
Pint Pharma Announces the Approval of ORLADEYO (Berotralstat), the First Oral Therapy Indicated to Prevent Hereditary Angioedema (HAE) Attacks in Adults and Children 12 Years and Older in Peru.
LIMA, Peru--(BUSINESS WIRE)--#angioedemahereditario--It is a great pleasure to announce that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has approved the daily oral use
No Data